Biofeedback for Dysfunctional Voiding and Giggle Incontinence
Biofeedback for Dysfunctional Voiding and Giggle Incontinence in Children
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Locations
-
-
Kadikoy
-
Istanbul, Kadikoy, Turkey (Türkiye), 34000
- Sancaktepe Sehit Prof Dr Ilhan Varank Training and Research Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients diagnosed with dysfunctional voiding or giggle incontinence
- Patients treated with biofeedback therapy
Exclusion Criteria:
- Presence of anatomical or neurological problems
- Patients with missing data
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Giggle incontinence
Patients who received biofeedback therapy for giggle incontinence
|
Biofeedback therapy is a behavioral treatment method that helps patients become more aware of and gain better control over their pelvic floor muscles.
Using EMG electrodes, muscle activity is monitored and presented to the patient visually or audibly, enabling them to recognize and correct improper muscle contractions or relaxations that contribute to urinary incontinence.
|
|
Dysfunctional voiding
Patients who received biofeedback therapy for dysfunctional voiding
|
Biofeedback therapy is a behavioral treatment method that helps patients become more aware of and gain better control over their pelvic floor muscles.
Using EMG electrodes, muscle activity is monitored and presented to the patient visually or audibly, enabling them to recognize and correct improper muscle contractions or relaxations that contribute to urinary incontinence.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants with Biofeedback-Related Resolution
Time Frame: From enrollment to the end of treatment at 18 weeks
|
Participants achieved a complete response which means 100% improvement in resolution of incontinence and abnormal voiding pattern
|
From enrollment to the end of treatment at 18 weeks
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Predictive Factors of Treatment Response
Time Frame: 18 weeks
|
Age, gender, and diagnosis will be evaluated as potential predictive factors of treatment response
|
18 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Sadeghi M, Oskouie IM, Naserghandi A, Arvin A, Majidi Zolbin M. Exploring dysfunctional voiding in girls: a comprehensive literature review of assessment and management strategies. BMC Urol. 2025 Apr 12;25(1):87. doi: 10.1186/s12894-025-01772-0.
- Gonzalez-Maldonado AA, Garcia-Merida M. Giggle incontinence: a scoping review. Pediatr Res. 2024 Jun;95(7):1720-1725. doi: 10.1038/s41390-024-03065-y. Epub 2024 Feb 2.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- BF DV + Giggle
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.